Does Aetna Cover Tirzepatide (Mounjaro)?

What Tirzepatide Is and Why Coverage Matters

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA in May 2022 under the brand name Mounjaro for type 2 diabetes (T2D) [1]. In November 2023, the FDA approved a second formulation, Zepbound, specifically for chronic weight management in adults with a BMI of 30 or above, or BMI <27 with at least one weight-related comorbidity [2].

These are not interchangeable from a formulary standpoint. Even though both products contain tirzepatide, Aetna (and most other payers) evaluate Mounjaro and Zepbound under separate benefit categories. Mounjaro falls under the diabetes drug benefit; Zepbound falls under the obesity or weight-management benefit. That distinction drives everything downstream.

Why the price makes coverage essential

Without insurance, a four-week supply of Mounjaro costs approximately $1,023 at major retail pharmacies [3]. The SURMOUNT-1 trial (N=2,539) showed that tirzepatide 15 mg produced a mean body weight reduction of 20.9% at 72 weeks versus 3.1% for placebo (P<0.001) [4]. Results that dramatic have generated enormous patient demand, and insurers are responding with tight utilization controls.

FDA-labeled indications and why they matter for claims

Aetna uses FDA-labeled indications as the primary gateway for coverage decisions. A claim submitted with ICD-10 code E11.x (type 2 diabetes) for Mounjaro has a substantially higher approval rate than a claim submitted with Z68.x (BMI) or E66.x (obesity) codes alone. Providers writing prescriptions for off-label weight management on a Mounjaro NDC rather than the Zepbound NDC may inadvertently trigger a denial.

How Aetna Structures Its Tirzepatide Formulary

Aetna operates multiple plan types, and formulary placement of tirzepatide varies across them. The broad categories are Aetna commercial (employer-sponsored), Aetna Medicare Advantage, and Aetna Medicaid.

Commercial plans

Most Aetna commercial formularies place Mounjaro on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier placement affects your copay but not the prior authorization requirement, which applies at every tier. Members whose employers have elected a value-based or narrow formulary may find tirzepatide non-covered entirely, even with a T2D diagnosis.

The American Diabetes Association's 2024 Standards of Care in Diabetes state that GLP-1 receptor agonists and dual GIP/GLP-1 agonists are preferred agents for T2D patients with established cardiovascular disease or high cardiovascular risk, heart failure, or chronic kidney disease [5]. Citing this guideline language in a prior authorization request can strengthen the clinical justification.

Medicare Advantage and Part D

Federal law currently prohibits Medicare Part D from covering drugs used exclusively for weight loss or weight management [6]. Mounjaro prescribed for T2D is covered under Part D. Zepbound prescribed for obesity is not covered by standard Medicare Part D, though the Treat and Reduce Obesity Act (TROA), if enacted, would change this.

Aetna Medicare Advantage plans follow the same federal restriction. Some Medicare Advantage plans have added supplemental obesity drug benefits through their Part C authority, but as of 2025, Aetna's Medicare Advantage plans do not uniformly include Zepbound in that supplemental benefit. Check your specific plan's Evidence of Coverage document.

Aetna Medicaid

Aetna administers Medicaid managed care in several states. Medicaid coverage of GLP-1 and dual GIP/GLP-1 agonists is highly state-specific. Some states, such as Louisiana and Colorado, have added tirzepatide to their Medicaid preferred drug lists under specific clinical criteria. Others have not. A January 2024 analysis from the Commonwealth Fund found that fewer than half of state Medicaid programs cover at least one GLP-1 agonist for obesity without severe restrictions [7].

Prior Authorization: What Aetna Typically Requires

Prior authorization (PA) is the single biggest barrier most patients face. Aetna's PA criteria for Mounjaro in T2D typically include the following elements, though exact criteria vary by plan year and employer group.

Clinical criteria for type 2 diabetes

Aetna generally requires documentation that:

• The member has a confirmed T2D diagnosis (HbA1c above 7.0% on a recent lab).
• Metformin was tried and either failed to achieve glycemic control or was contraindicated or not tolerated.
• The prescriber is an endocrinologist, primary care physician, or other licensed provider managing the diabetes.
• The prescribed dose matches Mounjaro's FDA-approved dosing schedule (2.5 mg weekly titrated up to a maximum of 15 mg weekly) [1].

The 2024 ADA Standards of Care note that for patients with T2D and BMI >35 who have not achieved individualized HbA1c goals on oral agents, a GIP/GLP-1 dual agonist is a reasonable next step without requiring prior failure of injectable insulin [5].

Clinical criteria for weight management (Zepbound)

For Zepbound under commercial obesity benefits, Aetna typically requires:

• BMI of 30 or above, or BMI <27 with an obesity-related comorbidity (hypertension, dyslipidemia, T2D, obstructive sleep apnea).
• Documentation of a structured weight management program attempted for at least 3 to 6 months.
• A prescriber attestation that the medication is part of a comprehensive weight-management plan including diet and physical activity.

The SURMOUNT-2 trial (N=938), which enrolled adults with T2D and obesity, showed a mean weight reduction of 15.7% with tirzepatide 15 mg versus 3.3% with placebo at 72 weeks [8]. Submitting this level of clinical evidence alongside the PA request may help.

Step therapy requirements

Step therapy means the insurer requires you to try and fail cheaper drugs before approving the requested medication. For Mounjaro, Aetna step therapy commonly requires prior use of:

1. Metformin (unless contraindicated).
2. One sulfonylurea or SGLT-2 inhibitor (plan-dependent).

For Zepbound, step therapy under an obesity benefit may require a trial of phentermine/topiramate (Qsymia) or naltrexone/bupropion (Contrave) first, though this varies significantly by plan.

How to File a Prior Authorization and What to Include

A well-prepared PA submission reduces denial rates. The following checklist reflects what Aetna's medical necessity criteria commonly require, based on published Aetna Clinical Policy Bulletins [9].

• Complete ICD-10 diagnosis codes (E11.x for T2D; E66.x plus BMI code for obesity).
• Recent HbA1c lab result (within 6 months) or documented BMI measurement.
• List of prior medications tried, with dates and reason for discontinuation.
• Current prescriber name, NPI, and specialty.
• Requested dose and expected titration schedule.
• Brief clinical narrative explaining why tirzepatide is appropriate for this patient.

Aetna must respond to standard PA requests within 3 business days and to urgent requests within 24 to 72 hours under NCQA utilization management standards [10].

Appealing a Denial

Aetna denies a meaningful share of first-time GLP-1 PA requests. Denial does not mean permanent denial.

Level 1 internal appeal

Submit a Level 1 appeal within 180 days of the denial notice for most commercial plans. Attach updated clinical notes, relevant trial data (SURPASS-2, SURMOUNT-1), and any guidelines supporting medical necessity. The ADA 2024 statement that GIP/GLP-1 agonists reduce cardiovascular events in high-risk T2D patients is a strong supporting document [5].

Independent external review

If the internal appeal fails, federal law (under the ACA) entitles most members to an independent external review by an accredited independent review organization (IRO). The IRO's decision is binding on the insurer. Data from the Kaiser Family Foundation show that patients win roughly 40 to 60% of external reviews for specialty drug denials [11].

Peer-to-peer review

Before or alongside a formal appeal, request a peer-to-peer (P2P) review. This is a phone call between your prescribing physician and Aetna's medical reviewer. P2P calls resolve a significant portion of PA denials without escalating to formal appeals, particularly when the prescriber can cite guideline language and patient-specific clinical complexity.

Out-of-Pocket Cost Strategies When Coverage Is Denied or Incomplete

Even with coverage, cost-sharing can be substantial. Several pathways may reduce what you pay.

Lilly's savings programs

Eli Lilly offers a Mounjaro savings card for commercially insured patients. Eligible patients may pay as little as $25 for a 1-month or 3-month prescription, subject to a maximum annual savings amount. As of 2024, that cap is $150 per month (up to $1,800 per year) for Mounjaro [3]. The savings card cannot be used by patients with federal insurance (Medicare, Medicaid, TRICARE).

Lilly also operates the Lilly Insulin Value Program and, separately, a patient assistance program (PAP) for uninsured patients who meet income thresholds. The PAP provides Mounjaro at no cost to qualifying patients.

Compounded tirzepatide: a cautionary note

During the FDA drug shortage period (which ended for Mounjaro in late 2024), compounding pharmacies produced tirzepatide for a fraction of the brand price. The FDA has stated that once a drug shortage is resolved, compounding of that drug is no longer permissible under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act [12]. Patients using compounded tirzepatide face uncertain quality, potency, and legal status. The FDA issued a formal alert in October 2024 warning that compounded tirzepatide products are not FDA-approved and may pose safety risks [12].

Telehealth and cash-pay programs

Some telehealth providers offer Mounjaro or Zepbound through employer-sponsored cash-pay arrangements or subscription models that bypass insurance. Monthly costs in these models typically range from $200 to $600 depending on dose, pharmacy partner, and whether the visit fee is bundled. These arrangements do not count toward your insurance deductible.

Coverage Differences: Mounjaro vs. Zepbound at Aetna

The table below summarizes how Aetna treats the two tirzepatide formulations differently.

| Feature | Mounjaro (T2D) | Zepbound (Obesity) | |---|---|---| | Primary ICD-10 | E11.x (T2D) | E66.x + BMI code | | Typical Aetna tier | Tier 3 to 4 | Tier 4 or non-covered | | PA required | Yes | Yes | | Step therapy | Metformin +/- one other agent | Behavioral program + possibly prior obesity drug | | Medicare Part D coverage | Yes (T2D indication) | No (federal law) | | Lilly savings card eligible | Yes (commercially insured) | Yes (commercially insured) | | Compounding permitted | No (shortage resolved) | No |

What Endocrinologists and Obesity Medicine Specialists Recommend

Providers managing patients on tirzepatide have developed practical workflows to manage coverage hurdles.

Documentation at the point of care

Entering the correct ICD-10 code at every visit matters. A single visit coded as a "weight management" visit (Z71.3) rather than a "type 2 diabetes management" visit (E11.65) can create a paper trail that an insurer uses to argue the drug is being prescribed for an obesity indication rather than glycemic control.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that dual GIP/GLP-1 agonists have "the strongest evidence base for weight reduction currently available for any pharmacological agent" and should be considered first-line when pharmacotherapy is indicated [13]. Including this quotation verbatim in PA letters has clinical and rhetorical weight.

Timing the PA before starting the drug

Prescribers who submit a PA before writing the prescription avoid the scenario where a patient starts tirzepatide on a manufacturer savings card, then faces a gap in therapy if the PA is denied or the savings card runs out. Starting with a PA also generates a documented approval that protects continuity of coverage if the patient changes jobs or plan years.

Switching between Mounjaro and Zepbound

A patient stabilized on Mounjaro for T2D who also has obesity may wish to switch to Zepbound if the employer plan covers the obesity indication at a lower tier. Clinically, the active ingredient is identical. From a formulary standpoint, this is a new PA request under a different NDC and benefit category. The transition should be planned with the prescriber and pharmacy benefit manager in advance to avoid a coverage gap.

Specific Aetna Plan Types and Tirzepatide Coverage Status

Coverage is not uniform across Aetna's plan portfolio. The following summaries reflect general patterns as of 2025.

Aetna Open Choice PPO

Most large-employer Aetna Open Choice PPO plans include Mounjaro on the formulary for T2D with PA. Zepbound coverage depends on whether the employer elected the obesity drug rider, which is an optional benefit employers must affirmatively add. Many employers have opted out due to cost.

Aetna Select (HMO)

Aetna Select HMO plans generally mirror the PPO formulary but may have narrower specialty networks. The PA process is the same, but the HMO requires the PCP to initiate the referral or PA request in some plan designs.

Aetna Medicare Advantage

As noted above, Mounjaro is covered for T2D. Zepbound is not covered under standard Medicare Advantage as of 2025. Out-of-pocket costs for Mounjaro under Medicare Part D depend on the phase of the benefit (deductible, initial coverage, catastrophic). The Inflation Reduction Act's $35/month insulin cap does not apply to GLP-1 agonists, though the $2,000 annual out-of-pocket cap that took effect in 2025 may reduce total annual exposure for members in the coverage gap [6].

Aetna Student Health Plans

University-sponsored Aetna student health plans vary widely. Some cover Mounjaro with PA; others exclude all GLP-1 and dual agonist drugs by category. Students should call the number on the back of their insurance card and ask specifically whether tirzepatide appears on the current formulary.

How to Check Your Specific Aetna Plan

No single answer covers every Aetna plan because employer groups customize their benefit designs. The most reliable way to confirm coverage is a three-step process.

1. Pull up the current formulary: Log into your Aetna member portal at aetna.com and search the drug formulary for "tirzepatide" or "Mounjaro." Note the tier and any PA or step therapy flags.
2. Call the pharmacy benefits line: The number on the back of your insurance card routes to pharmacy benefits. Ask specifically: "Is tirzepatide (Mounjaro) covered for type 2 diabetes under my plan? What are the prior authorization criteria?"
3. Ask your prescriber's office to run a benefits investigation: Most specialty pharmacies and endocrinology practices will complete an insurance benefits verification at no charge before submitting the prescription.

The SURPASS-2 trial (N=1,879), which compared tirzepatide directly against semaglutide 1 mg for T2D management, found that tirzepatide 15 mg reduced HbA1c by a mean of 2.58% versus 1.86% for semaglutide, and produced 11.2 kg greater weight loss at 40 weeks (P<0.001) [14]. Presenting comparative efficacy data like this in a PA appeal, particularly when a plan is willing to cover semaglutide but not tirzepatide, can support a non-inferiority or superiority argument.